Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-11-06 Sale | 2024-11-08 4:53 pm | Spyre Therapeutics Inc. | SYRE | Albers Jeffrey W. Director | 6,700 | $36.76 | $246,313 | 27,360 (Indirect) | View |
| 2024-10-25 Sale | 2024-10-28 4:41 pm | Spyre Therapeutics Inc. | SYRE | Albers Jeffrey W. Director | 300 | $36.43 | $10,929 | 34,060 (Indirect) | View |
| 2024-09-03 Sale | 2024-09-05 4:04 pm | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 18,531 | $28.17 | $522,074 | 116,422 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2025-01-15 Option Award | 2025-01-17 4:36 pm | N/A 2035-01-15 | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 95,500 | $0 | 95,500 (Direct) | View |
| 2025-01-15 Option Award | 2025-01-17 4:36 pm | N/A 2035-01-15 | Spyre Therapeutics Inc. | SYRE | Sloan Sheldon Chief Medical Officer | 95,500 | $0 | 95,500 (Direct) | View |
| 2025-01-15 Option Award | 2025-01-17 4:35 pm | N/A 2035-01-15 | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 370,000 | $0 | 370,000 (Direct) | View |
| 2025-01-15 Option Award | 2025-01-17 4:34 pm | N/A 2035-01-15 | Spyre Therapeutics Inc. | SYRE | King-Jones Heidy See Remarks | 95,500 | $0 | 95,500 (Direct) | View |
| 2025-01-10 Other | 2025-01-14 5:16 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | HENDERSON MICHAEL THOMAS Director | 105,379 | $0 | 210,758 (Direct) | View |
| 2024-10-01 Option Award | 2024-10-01 6:34 pm | N/A 2034-10-01 | Spyre Therapeutics Inc. | SYRE | Sloan Sheldon Chief Medical Officer | 400,000 | $0 | 400,000 (Direct) | View |
| 2024-05-14 Option Award | 2024-05-16 4:10 pm | N/A 2034-05-14 | Spyre Therapeutics Inc. | SYRE | Fairmount Funds Management LLC Kiselak Tomas Harwin Peter Evan Director | 22,646 | $0 | 22,646 (Indirect) | View |
| 2024-05-14 Option Award | 2024-05-16 4:10 pm | N/A 2034-05-14 | Spyre Therapeutics Inc. | SYRE | Milligan Sandra Director | 21,980 | $0 | 21,980 (Direct) | View |
| 2024-05-14 Option Award | 2024-05-16 4:10 pm | N/A 2034-05-14 | Spyre Therapeutics Inc. | SYRE | Albers Jeffrey W. Director | 11,323 | $0 | 11,323 (Direct) | View |
| 2024-05-14 Option Award | 2024-05-16 4:10 pm | N/A 2034-05-14 | Spyre Therapeutics Inc. | SYRE | Stelzer Laurie Director | 11,323 | $0 | 11,323 (Direct) | View |
| 2024-05-14 Option Award | 2024-05-16 4:10 pm | N/A 2034-05-14 | Spyre Therapeutics Inc. | SYRE | HENDERSON MICHAEL THOMAS Director | 11,323 | $0 | 11,323 (Direct) | View |
| 2024-04-25 Exercise | 2024-04-25 4:55 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director | 3,730,672 | $0 | 5,176,222 (Indirect) | View |
| 2024-02-15 Option Award | 2024-02-20 9:21 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 400 | $9.82 | 746,907 (Direct) | View |
| 2024-02-01 Option Award | 2024-02-05 5:29 pm | N/A 2034-02-01 | Spyre Therapeutics Inc. | SYRE | McKenna Mark C. Director | 40,000 | $0 | 40,000 (Direct) | View |
Ownership | 2024-02-05 5:25 pm | N/A 2033-11-22 | Spyre Therapeutics Inc. | SYRE | McKenna Mark C. Director | 0 | $0 | 477,000 (Direct) | View |
| 2024-02-01 Option Award | 2024-02-02 8:31 pm | N/A 2034-02-01 | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 277,750 | $0 | 277,750 (Direct) | View |
| 2024-02-01 Option Award | 2024-02-02 8:27 pm | N/A 2034-02-01 | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 70,000 | $0 | 70,000 (Direct) | View |
| 2024-02-01 Option Award | 2024-02-02 8:23 pm | N/A 2034-02-01 | Spyre Therapeutics Inc. | SYRE | King-Jones Heidy See Remarks | 63,000 | $0 | 63,000 (Direct) | View |
| 2023-12-29 Other | 2023-12-29 5:00 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner | 3,841,518 | $0 | 5,485,719 (Indirect) | View |
| 2023-12-22 Option Award | 2023-12-22 6:00 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 134,953 | $0 | 134,953 (Direct) | View |
| 2023-12-07 Option Award | 2023-12-11 5:41 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner | 16,667 | $600 | 16,667 (Indirect) | View |
| 2023-11-24 Conversion(A) | 2023-12-08 4:07 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Albers Jeffrey W. Director | 35,219 | $0 | 84,360 (Indirect) | View |
| 2023-11-22 Option Award(A) | 2023-12-08 4:07 pm | N/A 2033-11-22 | Spyre Therapeutics Inc. | SYRE | Albers Jeffrey W. Director | 50,000 | $0 | 84,360 (Direct) | View |
Ownership(A) | 2023-12-08 4:03 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Albers Jeffrey W. Director | 0 | $0 | 34,360 (Indirect) | View |
| 2023-11-24 Conversion | 2023-11-28 4:05 pm | N/A N/A | Spyre Therapeutics Inc. | AGLE | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner | 3,521,367 | $0 | 4,250,938 (Indirect) | View |
| 2023-11-22 Option Award | 2023-11-27 4:36 pm | N/A 2033-11-22 | Spyre Therapeutics Inc. | AGLE | Albers Jeffrey W. Director | 50,000 | $0 | 50,000 (Direct) | View |
| 2023-11-22 Option Award | 2023-11-27 4:33 pm | N/A 2033-11-22 | Spyre Therapeutics Inc. | AGLE | Stelzer Laurie Director | 50,000 | $0 | 50,000 (Direct) | View |
| 2023-11-24 Conversion | 2023-11-27 4:25 pm | N/A N/A | Spyre Therapeutics Inc. | AGLE | Turtle Cameron Chief Executive Officer | 741,526 | $0 | 1,120,507 (Direct) | View |
| 2023-11-22 Option Award | 2023-11-27 4:25 pm | N/A 2033-11-22 | Spyre Therapeutics Inc. | AGLE | Turtle Cameron Chief Executive Officer | 374,000 | $0 | 1,120,507 (Direct) | View |
| 2023-09-01 Option Award | 2023-09-05 4:15 pm | N/A 2033-09-01 | Aeglea BioTherapeutics Inc. | AGLE | King-Jones Heidy See Remarks | 13,495,255 | $0 | 13,495,255 (Direct) | View |
| 2023-09-01 Option Award | 2023-09-05 4:10 pm | N/A 2033-09-01 | Aeglea BioTherapeutics Inc. | AGLE | Burrows Scott L Chief Financial Officer | 10,121,441 | $0 | 10,121,441 (Direct) | View |
Ownership | 2023-06-30 5:32 pm | N/A N/A | Aeglea BioTherapeutics Inc. | AGLE | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner | 0 | $0 | 536,284,540 (Indirect) | View |
Ownership | 2023-06-30 5:14 pm | N/A N/A | Aeglea BioTherapeutics Inc. | AGLE | Turtle Cameron Chief Operating Officer | 0 | $0 | 65,959,896 (Direct) | View |